Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

Inclusion Criteria

• •1. Age ≥ 3months and ≤18years;
• •2. Histopathologically confirmed low-grade glioma (WHO grade I and II), including astrocytoma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, infantile desmoplastic astrocytoma, low-grade oligodendroglioma, oligoastrocytoma, ganglioglioma, and infantile desmoplastic ganglioglioma. Chiasmatic-hypothalamic tumors intrinsic to the optic pathway were eligible without pathologic confirmation.
• •3. There is a clear evaluable lesion with less than 95% resection or residual tumor of more than 1.5 cm\^2；
• •4. KPS score ≥50 (age\> 12 years old) or Lansky score ≥ 50 (age ≤ 12 years old)；
• •5. Estimated survival of at least 12 weeks;
• •6. Have not been received radiotherapy or chemotherapy before；
• •7. Participants must have adequate organ function as defined by the following criteria (within 7 days before treatment):
• •Hematology (No transfusion within 14 days):
• •Hemoglobin(HB)≥90g/L; Absolute neutrophil count (ANC)≥1.5×10\^9/L; Platelet (PLT)≥80×10\^9/L.
• •Chemistry:
• •Serum bilirubin ≤ 1.5×upper limit of normal (ULN) ALT and AST≤2.5ULN； Serum creatinine ≤1.5ULN or creatinine clearance rate(CCr)≥60ml/min； ECG: heart rate in the normal range (55-100beats/min), normal or slightly prolonged QT interval (QTc\<480ms), normal or low T wave, normal or non-specific ST segment changes；
• •8. The patient or his legal guardian signs an informed consent form.